Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tenaya Therapeutics Inc (TNYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: TNYA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 9.5% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 88.45M USD | Price to earnings Ratio - | 1Y Target Price 12.62 |
Price to earnings Ratio - | 1Y Target Price 12.62 | ||
Volume (30-day avg) 4545131 | Beta 2.84 | 52 Weeks Range 0.39 - 5.10 | Updated Date 04/2/2025 |
52 Weeks Range 0.39 - 5.10 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
Earnings Date
Report Date 2025-03-11 | When - | Estimate -0.315 | Actual -0.28 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -49.9% | Return on Equity (TTM) -95.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40606959 | Price to Sales(TTM) - |
Enterprise Value 40606959 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.67 | Shares Outstanding 162583008 | Shares Floating 60476693 |
Shares Outstanding 162583008 | Shares Floating 60476693 | ||
Percent Insiders 1.42 | Percent Institutions 106.79 |
Analyst Ratings
Rating 4.67 | Target Price 18.5 | Buy 3 | Strong Buy 6 |
Buy 3 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tenaya Therapeutics Inc
Company Overview
History and Background
Tenaya Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering therapies to treat heart disease. It was founded in 2016 and is based in South San Francisco, California. Its mission is to dramatically improve the lives of individuals suffering from heart disease.
Core Business Areas
- Gene Therapy: Developing adeno-associated virus (AAV) gene therapies to deliver functional genes to the heart, aiming to correct genetic defects.
- Small Molecule: Discovering and developing small molecule drugs that modulate key biological pathways involved in heart disease.
- Precision Medicine: Using precision medicine approaches to identify patients who are most likely to benefit from Tenaya's therapies.
Leadership and Structure
Faraz Ali, Ph.D., is the Chief Executive Officer. The organizational structure includes research, development, clinical, and commercial teams. They also have a board of directors with extensive experience in the biotech and pharmaceutical industries.
Top Products and Market Share
Key Offerings
- TN-201 (MYBPC3 gene therapy): An AAV gene therapy designed to treat hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene. Currently in clinical trials (Phase 1b). Competitors include companies developing therapies for HCM, like Cytokinetics (OMK-544).
- TN-301 (PKP2 gene therapy): An AAV gene therapy designed to treat arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the PKP2 gene. Currently in preclinical development. Competitors may include companies like Sarepta Therapeutics, which are also developing gene therapies.
Market Dynamics
Industry Overview
The cardiovascular disease therapeutics market is a large and growing market driven by an aging population and increasing prevalence of heart disease. Gene therapy for cardiac diseases is still a relatively nascent but promising field.
Positioning
Tenaya is positioned as a leader in developing gene therapies for heart disease, with a focus on precision medicine approaches. Its competitive advantages include its scientific expertise, experienced management team, and strong intellectual property portfolio.
Total Addressable Market (TAM)
The TAM for gene therapies targeting specific genetic cardiomyopathies is estimated to be in the billions of dollars globally. Tenaya is positioned to capture a significant share of this market by focusing on underserved patient populations with high unmet needs.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in cardiac gene therapy
- Experienced management team
- Focus on precision medicine
- Proprietary gene therapy platform
- Strong intellectual property position
Weaknesses
- Early-stage clinical development (high risk)
- Dependence on regulatory approvals
- High cash burn rate
- Competition from established pharmaceutical companies
- Limited commercialization experience
Opportunities
- Positive clinical trial results
- Expansion of pipeline into new cardiac indications
- Strategic partnerships with pharmaceutical companies
- Breakthrough Therapy designation from regulatory agencies
- Increasing awareness of gene therapy as a treatment option
Threats
- Clinical trial failures
- Regulatory delays
- Competition from other gene therapy companies
- Adverse events associated with gene therapy
- Pricing and reimbursement challenges
Competitors and Market Share
Key Competitors
- SRPT
- BLUE
- CYTK
Competitive Landscape
Tenaya faces competition from established pharmaceutical companies and other gene therapy companies in the cardiovascular space. Tenaya's advantages include its focus on specific genetic cardiomyopathies and its precision medicine approach. Disadvantages include its early stage of development and limited resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Tenaya's growth has been driven by the advancement of its gene therapy programs through preclinical and clinical development stages.
Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approvals, and commercial launch of its gene therapies. Analysts' estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials, expanding its pipeline through strategic partnerships, and presenting data at scientific conferences.
Summary
Tenaya Therapeutics is a promising biotechnology company focused on developing gene therapies for heart disease. While its early-stage clinical development presents risks, its innovative approach, strong scientific team, and focus on precision medicine position it for future growth. Successfully navigating clinical trials and securing regulatory approvals are key for its success, while ongoing market competition remains a factor.
Similar Companies
- SRPT
- BLUE
- CYTK
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tenaya Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-07-30 | CEO, Interim Principal Financial Officer & Director Mr. Faraz Ali M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | |
Full time employees 97 | |||
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction which is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.